Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q2

7459.TEDINET S100PLGZ
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥1.69T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥3.29T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.64T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥25.5bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥24.3bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥33.3bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥62.0bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥33.6bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥33.3bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥34.0bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥17.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥21.9bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥23.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.74Tat 2022-09-30Cons.Assets
Total assets¥1.71Tat 2022-03-31Cons.Assets
Total assets¥1.72Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.06Tat 2022-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2022-03-31Cons.Liabilities
Net assets / equity¥674.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥649.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥657.2bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥221.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥243.2bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥238.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥260.4bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥239.6bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥240.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥9.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥24.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥5.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥24.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥16.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥82.512022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.132022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥140.142021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.232021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥43.252021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥77.562022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥131.412021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥82.792021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio31.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.0%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥191m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥36.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥554.9bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥554.7bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥174m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.10T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥25.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥304m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.9bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥531.6bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥531.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥175m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.3bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.08T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.65T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.64T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Noncurrent liabilitiesCurrentQuarterInstant54606000000JPY
LiabilitiesPrior1YearInstant1060384000000JPY
LiabilitiesCurrentQuarterInstant1060535000000JPY
Capital stockPrior1YearInstant22398000000JPY
Capital stockCurrentQuarterInstant22398000000JPY
Capital surplusPrior1YearInstant133922000000JPY
Capital surplusCurrentQuarterInstant133922000000JPY
Retained earningsPrior1YearInstant385611000000JPY
Retained earningsCurrentQuarterInstant398070000000JPY
Treasury stockPrior1YearInstant-58612000000JPY
Treasury stockCurrentQuarterInstant-58613000000JPY
Shareholders equityPrior1YearInstant483320000000JPY
Shareholders equityCurrentQuarterInstant495778000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant58956000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant67431000000JPY
Deferred gains or losses on hedgesPrior1YearInstant5000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant33000000JPY
Revaluation reserve for landPrior1YearInstant-13737000000JPY
Revaluation reserve for landCurrentQuarterInstant-13700000000JPY
Foreign currency translation adjustmentPrior1YearInstant1178000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant2082000000JPY
Remeasurements of defined benefit plansPrior1YearInstant580000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant337000000JPY
Valuation and translation adjustmentsPrior1YearInstant46984000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant56184000000JPY
Non controlling interestsPrior1YearInstant118784000000JPY
Non controlling interestsCurrentQuarterInstant122781000000JPY
Net assetsPrior1YearInstant649089000000JPY
Net assetsCurrentQuarterInstant674745000000JPY
Liabilities and net assetsPrior1YearInstant1709474000000JPY
Liabilities and net assetsCurrentQuarterInstant1735280000000JPY
Net salesPrior1YTDDuration1643244000000JPY
Net salesCurrentYTDDuration1685396000000JPY
Cost of salesPrior1YTDDuration1534399000000JPY
Cost of salesCurrentYTDDuration1573846000000JPY
Gross profitPrior1YTDDuration108844000000JPY
Gross profitCurrentYTDDuration111550000000JPY
Salaries and allowances sgaPrior1YTDDuration32432000000JPY
Salaries and allowances sgaCurrentYTDDuration32051000000JPY
Welfare expenses sgaPrior1YTDDuration6240000000JPY
Welfare expenses sgaCurrentYTDDuration6278000000JPY
Provision for bonuses sgaPrior1YTDDuration6392000000JPY
Provision for bonuses sgaCurrentYTDDuration6649000000JPY
Retirement benefit expenses sgaPrior1YTDDuration1720000000JPY
Retirement benefit expenses sgaCurrentYTDDuration1500000000JPY
Distribution expenses sgaPrior1YTDDuration9454000000JPY
Distribution expenses sgaCurrentYTDDuration9562000000JPY
Rents sgaPrior1YTDDuration2171000000JPY
Rents sgaCurrentYTDDuration2048000000JPY
Depreciation sgaPrior1YTDDuration6158000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass